UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. パーキンソン病の薬理学的治療 pharmacologic treatment of parkinson disease
2. 薬剤誘発性の弁膜症 valvular heart disease induced by drugs
3. 乳腺刺激腺腫およびその他の原因による高プロラクチン血症の治療 treatment of hyperprolactinemia due to lactotroph adenoma and other causes
4. 多系統萎縮症：予後および治療 multiple system atrophy prognosis and treatment
5. トゥレット症候群 tourette syndrome

English Journal

Sreenan S, Sengupta E, Tormey W, Landau R.AbstractABSTRACT: INTRODUCTION: Asymptomatic pituitary abnormalities occur in about 10% of cranial magnetic resonance imaging scans, but metastatic carcinoma of the pituitary gland is rare: 133 cases have been reported. Two thirds secreted either prolactin or adrenocorticotropic hormone, and another 24% were non-secreting.
Journal of medical case reports.J Med Case Rep.2012 Sep 25;6(1):322. [Epub ahead of print]
ABSTRACT: INTRODUCTION: Asymptomatic pituitary abnormalities occur in about 10% of cranial magnetic resonance imaging scans, but metastatic carcinoma of the pituitary gland is rare: 133 cases have been reported. Two thirds secreted either prolactin or adrenocorticotropic hormone, and another 24% wer
PMID 23009369

Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.

Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, Shah BB, Fox S, Prashanth LK, Phielipp N, Lang AE.SourceThe Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Journal of neurology, neurosurgery, and psychiatry.J Neurol Neurosurg Psychiatry.2012 Aug 29. [Epub ahead of print]
BACKGROUND: Recently, symptoms similar to addictive drug withdrawal have been reported in a structured longitudinal study of patients with idiopathic Parkinson's Disease (PD) withdrawing from dopamine agonists (DA): the dopamine agonist withdrawal syndrome (DAWS).OBJECTIVES: The objective of this st
PMID 22933817

薬物療法主な治療薬の種類と特徴ドパミン受容体作動薬--概要,薬理作用,用法・用量,有用性,副作用とその対策ペルゴリド (パーキンソン病--基礎・臨床研究のアップデート) -- (治療)

Effects of Pergolide Mesilate on Metallothionein mRNAs Expression in a Mouse Model for Parkinson Disease

Ono Shin-ichi,Hirai Kohji,Tokuda Ei-ichi
Biological and Pharmaceutical Bulletin 32(10), 1813-1817, 2009
… We examined the effects of pergolide mesilate (PM) on the levels of metallothionein mRNA expression and lipid peroxidation in the corpus striata of 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian mice. …
NAID 130000116949